April Cashin-Garbutt of News-Medical interviewing Chris Rowland, CEO, Medigus, about the long-term treatment of GERD
Renowned German Gastroenterologist Dr. Karel Caca Completes Third MUSE Procedure
Incisionless procedure that is gaining worldwide adoption is now available at top-rated U.S. hospital in Baltimore
Over 90% of patients maintained normalized quality of life measures in long-term follow-up
Medigus Ltd.: Leading GI Surgeon Professor Pier Alberto Testoni Among First to Perform New MUSE™ Procedure For Treatment of GERD In Italy
Broader adoption of MUSE strengthens Medigus' growth potential in Europe following completion of several procedures in leading healthcare institutions
Medigus Announces American Medical Association (AMA) Publication of Category I CPT Code for Esophagogastric Fundoplasty Trans-Orifice Procedures
Code Represents Important First Step In Process To Gain Coverage For Incisionless Procedures To Treat The Underlying Cause Of GERD.
Final Code Scheduled to Take Effect January 2016
CEO Chris Rowland Scheduled to Present on March 11, 2015 at 10:00 a.m. PDT
New agreement represents at least $17.6 million over four years, following CFDA approval.